The $21 Billion Bet: What Abbott-Exact Sciences Means for the Future of Liquid Biopsy
Abbott's $21B Exact Sciences acquisition caps a quarter of mega-deals, FDA filings, and legislation that signals liquid biopsy's shift from innovation to infrastructure.
Articles
September 17, 2026
